BlossomHill Therapeutics 3Q 2026: EPS ($1.29) — 10-Q Summary
BlossomHill Therapeutics reported a wider net loss of $24.01M in 3Q 2026, up 50.3% YoY, due to increased R&D and manufacturing costs. Diluted EPS was ($1.29). The company advanced clinical trials for BH-30643 and BH-501284, with FDA alignment and Fast Track designation for BH-30643. Cash runway extends into 2Q 2028.
How this was made
The 30-second read
Why it matters
The earnings miss and widened loss are likely to trigger short‑term price decline, while trial milestones may temper the downside for longer‑term investors.
Market read
Primary earnings disclosure for a micro‑cap biotech; fresh data with material impact on the stock.
What to watch
Cash runway into 2028 and upcoming IND filing may support future funding expectations.
Background
BlossomHill Therapeutics filed its Q3 2026 10‑Q, providing the first public disclosure of its quarterly financials and clinical updates.
Ticker impact
Q3 2026 10-Q shows net loss widening 50% YoY to $24.01M and EPS of -$1.29, plus Fast Track designation for BH-30643 and trial updates.
downward pressure as investors price the larger loss despite trial progress
The disclosed loss expansion and negative EPS are fresh data; market typically reacts negatively to widening losses.
Market effects
Biotech sector may see modest pullback as earnings miss highlights cash burn risks.
US biotech investors could adjust exposure to early‑stage clinical companies.
Limited; impact confined to niche biotech investors.
Counterpoint
Trial progress and Fast Track status could be a catalyst for upside if investors focus on long‑term potential.
Key entities
- companyBlossomHill Therapeutics
US‑listed biotech (ticker BLSM) reporting Q3 2026 results.